Clinical Trial Update: Dermata Achieves 50% Enrollment in DMT310 Phase 3 STAR-1 Clinical Trial for Acne
Fully 50% of patients are now enrolled in Dermata’s pivotal Phase 3 Spongilla Treatment for Acne Research (STAR-1) study of DMT310, the Company reports. The STAR-1 study is the first of two Phase 3 studies that, if positive, would be used by the Company to support the filing of a new drug application (NDA) for […]